Novo Nordisk buys treatment candidate for rare disease for up to USD 1.2bn

Biotech company Prothena is selling the drug candidate treatment for ATTR amyloidosis. Novo Nordisk's initial focus is a particular variant of the disease which affects the heart.

Photo: Novo Nordisk / PR

Novo Nordisk has taken over Prothena's drug candidate PRX004, which is being developed to treat ATTR amyloidosis. In the same deal, Novo Nordisk is taking over Prothena's entire wide-ranging ATTR amyloidosis program.

Novo Nordisk has paid USD 100m upfront for the rights to the drug and the entire indication development program, but the agreed milestone payments may total up to USD 1.2bn.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs